All In Biotech

NDA 215721 · Almatica

Zolpidem Tartrate

Zolpidem Tartrate · Oral

Last checked: Nov 20, 2026Latest source record: May 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 9, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

142

25 Phase 3, 8 recruiting

FAERS reports

24,112

18,146 serious, 3,297 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem Tartrate Capsules. Some of these events may result in serious injuries, including death. Discontinue Zolpidem Tartrate Capsules immediately if a patient experiences a complex sleep behavior [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem Tartrate Capsules. Some of these events may result in serious injuries, including death. Discontinue Zolpidem Tartrate Capsules immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )

What it is approved for

From the label in effect Oct 9, 2025.

Zolpidem Tartrate Capsules are indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )] . Zolpidem Tartrate Capsules, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age ( 1 )

Mechanism: Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of transient insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZOLPIDEM TARTRATE · ZOLPIDEM TARTRATE 7.5MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zolpidem" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,450
  • nausea1,242
  • fatigue1,169
  • insomnia990
  • diarrhoea938
  • fall931
  • headache917
  • completed suicide894
  • pain809
  • vomiting805
  • dizziness801
  • drug abuse772

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004528
2005572
2006578
2007726
2008618
2009604
2010597
2011658
2012872
2013602
2014608
20151,045
20161,566
20171,288
20181,681
20191,470
20201,329
20211,243
20221,568
20231,543
20241,688
20251,540
20261,188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zolpidem Tartrate* (Zolpidem Tartrate)

2024 spending

$50.1M

Beneficiaries

1,483,094

7,548,054 claims

Per beneficiary

$34

$0.18 per unit

View as table
YearSpending
2020$54,198,267
2021$59,456,351
2022$61,526,022
2023$60,777,775
2024$50,113,170

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 490 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.